Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Shares of British pharmaceutical company Redx Pharma (LON: REDX) today surged 280% after the company revealed that it had signed a licensing deal with AstraZeneca for the commercial development of RXC006, a porcupine inhibition treatment for fibrotic diseases.
Redx stock traded as high as 95p having closed yesterday’s session at 25p, a huge 280% gain.
The company is set to receive up to $17 million as part of initial payments and could earn a further $360 million as various development and commercialisation milestones are achieved.
The firm is also eligible for tiered royalty payments set at mid-single-digit percentages based on future net sales figures.
The agreement will see AstraZeneca take RXC006 into clinical development with the end goal of treating fibrotic diseases such as idiopathic pulmonary fibrosis.
According to Redx Pharma, the RXC006 drug takes an innovative approach to treating fibrotic diseases.
Redx Pharma share price
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .